AMRX amneal.com: Company Value to Revenue Ratio

The company's price-to-sales ratio reflects the market consensus, where 3339.88 serves as the final level marker. Amneal Pharmaceuticals (AMRX) relies on a warehouse network and strict quality control to drive supply efficiency. The business is shifting its focus toward high-cost biosimilars and injectables, reducing the share of simple tablets. A stable economic moat is maintained through US-based production and compliance with rigorous industry standards.
Financial and market metric breakdowns for Amneal Pharmaceuticals Inc (AMRX)

Risks of substance shortages from Asia and logistics disruptions at Amneal Pharmaceuticals (AMRX) directly impact revenue volumes, making the EV/Sales calculation critical for assessing business value regardless of debt load. This ratio compares the total enterprise value to its sales, allowing the historical EV/Sales trend to determine whether the current discount results from undervaluation or a systemic decline of the asset.